AR095668A1 - Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas - Google Patents
Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismasInfo
- Publication number
- AR095668A1 AR095668A1 ARP140101274A ARP140101274A AR095668A1 AR 095668 A1 AR095668 A1 AR 095668A1 AR P140101274 A ARP140101274 A AR P140101274A AR P140101274 A ARP140101274 A AR P140101274A AR 095668 A1 AR095668 A1 AR 095668A1
- Authority
- AR
- Argentina
- Prior art keywords
- toxins
- methods
- disclosed
- compositions
- toxoids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
Abstract
Se revelan métodos para la producción de una toxina clostridial purificada que comprende una filtración de flujo tangencial, una cromatografía de interacción hidrofóbica y una cromatografía de intercambio de aniones. Estos métodos proporcionan buenos rendimientos de una toxina de C. difficile que tiene una pureza de aproximadamente 90% o mayor. También se revelan toxinas ciostridiales altamente purificadas, toxoides (por ej., preparados por medio de la inactivación de la toxina de acuerdo con lo revelado en la presente) y composiciones que comprenden estas toxinas y/o toxoides. También se revelan métodos para el uso de las toxinas purificadas y/o toxoides por ejemplo, para provocar una respuesta inmune contra clostridium (por ej., C. difficile).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793376P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095668A1 true AR095668A1 (es) | 2015-11-04 |
Family
ID=50489432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101274A AR095668A1 (es) | 2013-03-15 | 2014-03-18 | Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160030542A1 (es) |
| EP (1) | EP2970400A1 (es) |
| JP (1) | JP2016519671A (es) |
| KR (1) | KR20150133771A (es) |
| CN (1) | CN105308066A (es) |
| AR (1) | AR095668A1 (es) |
| AU (2) | AU2014228983B2 (es) |
| BR (1) | BR112015023469A8 (es) |
| CA (1) | CA2907156A1 (es) |
| HK (1) | HK1213917A1 (es) |
| SG (1) | SG11201507578PA (es) |
| TW (1) | TW201518316A (es) |
| WO (1) | WO2014144594A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9730994B2 (en) * | 2013-06-14 | 2017-08-15 | Sanofi Pasteur, Inc. | Compositions and methods for immunizing against C. difficile |
| CN108003224A (zh) * | 2017-12-20 | 2018-05-08 | 天康生物股份有限公司 | 一种多杀性巴氏杆菌毒素蛋白的纯化方法 |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) * | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| CN101801343A (zh) | 2007-07-26 | 2010-08-11 | 圣诺菲·帕斯图尔有限公司 | 抗原佐剂组合物及其方法 |
| EP2198007B1 (en) | 2007-09-14 | 2017-10-25 | Sanofi Pasteur Biologics, LLC | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2014
- 2014-03-14 CN CN201480021573.0A patent/CN105308066A/zh active Pending
- 2014-03-14 US US14/776,189 patent/US20160030542A1/en not_active Abandoned
- 2014-03-14 JP JP2016502977A patent/JP2016519671A/ja active Pending
- 2014-03-14 KR KR1020157029584A patent/KR20150133771A/ko not_active Application Discontinuation
- 2014-03-14 CA CA2907156A patent/CA2907156A1/en not_active Abandoned
- 2014-03-14 SG SG11201507578PA patent/SG11201507578PA/en unknown
- 2014-03-14 BR BR112015023469A patent/BR112015023469A8/pt not_active Application Discontinuation
- 2014-03-14 EP EP14717952.7A patent/EP2970400A1/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/029070 patent/WO2014144594A1/en active Application Filing
- 2014-03-14 AU AU2014228983A patent/AU2014228983B2/en not_active Ceased
- 2014-03-17 TW TW103110045A patent/TW201518316A/zh unknown
- 2014-03-18 AR ARP140101274A patent/AR095668A1/es unknown
-
2016
- 2016-02-18 HK HK16101839.5A patent/HK1213917A1/zh unknown
-
2018
- 2018-07-04 AU AU2018204879A patent/AU2018204879A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160030542A1 (en) | 2016-02-04 |
| CA2907156A1 (en) | 2014-09-18 |
| AU2014228983B2 (en) | 2018-04-05 |
| AU2014228983A1 (en) | 2015-10-08 |
| AU2018204879A1 (en) | 2018-07-26 |
| WO2014144594A8 (en) | 2014-11-13 |
| BR112015023469A8 (pt) | 2019-12-03 |
| SG11201507578PA (en) | 2015-10-29 |
| HK1213917A1 (zh) | 2016-07-15 |
| KR20150133771A (ko) | 2015-11-30 |
| EP2970400A1 (en) | 2016-01-20 |
| WO2014144594A1 (en) | 2014-09-18 |
| BR112015023469A2 (pt) | 2017-07-18 |
| JP2016519671A (ja) | 2016-07-07 |
| TW201518316A (zh) | 2015-05-16 |
| CN105308066A (zh) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018008901A8 (pt) | formulações subcutâneas de anticorpos anti-cd 38 e seus usos | |
| CL2018000829A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| BR112016013562A2 (pt) | Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas | |
| CR20140565A (es) | Proteínas de fusión de interleuquina 10 y usos de las mismas | |
| AR095668A1 (es) | Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas | |
| BR112016002391A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| TR201900360T4 (tr) | Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇ | |
| SG10201808151RA (en) | Cortistatin analogues and syntheses and uses thereof | |
| CO6751260A2 (es) | Vacunas basadas en omv contra infecciones por burkholderia | |
| BR112013005855A2 (pt) | heteroarilas fundidas e seus usos | |
| MX2017017124A (es) | 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot). | |
| CR20150314A (es) | Pirimido-[4,5-b]-quinolina-4,5 (3h, 10h)-dionas como supresoras de mutación sin sentido | |
| PE20151978A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo | |
| AR095669A1 (es) | Toxinas, composiciones y métodos relacionados | |
| BR112016001876A2 (pt) | composto de benzoxaborol tricíclico, método de preparação e uso do mesmo | |
| BR112018004861A2 (pt) | processo para purificação de hidrolisado de biomassa | |
| BR112019000290A2 (pt) | pró-fármacos de fósforo dos estimuladores da scg | |
| BR112015032388A8 (pt) | glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições | |
| BR112018069079A2 (pt) | construtos de alfavírus vivos atenuados e métodos e usos dos mesmos | |
| MX2016002870A (es) | Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles. | |
| BR112017018707A2 (pt) | composições compreendendo compostos de mentol como agentes suavizantes | |
| BR112016019893A2 (pt) | composições de glicoproteína sialilada e seus usos | |
| IN2014CH01392A (es) | ||
| MX2016009696A (es) | Formulaciones de antibióticos tópicas.. | |
| DOP2019000102A (es) | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |